Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by a heterogeneous array of resistance mechanisms. Activation...

Full description

Bibliographic Details
Main Authors: Molly Wilgucki, DO, Vincent Yeung, MD, Grace Ho, MD, Gabriela L. Bravo Montenegro, MD, Greg Jones, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:JTO Clinical and Research Reports
Subjects:
NSCLC
Osimertinib
MET
EGFR
Y1003N
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001205

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001205

Similar Items